Laboratory of Cellular Oncology Technical Files

Click here to return to main plasmids page
Click here to return to main plasmids page
	Paper Name	Reference	Lab Name	Distribute?	Resistance	Notes
Target	p7927	[1]	pZaf	yes	amp	LacZ sequences antagonize packaging?
	pSU-5697	[1]	pNafB	yes	blast	replaced by pfwB
	pU-5864	[1]	pNKaf	yes	amp
	pU-7064	[1]	pSNaf	yes	amp
	pU-7257	[1]	pQNaf	yes	amp
	pU-7452	[1]	pZNaf	yes	amp
	pU-7981	[1]	pVNaf	yes	amp
	pU-10151	[1]	pWNaf	yes	amp
	pU-12781	[1]	pXNaf	yes	amp
	pU-GFP	[1]	pNf	yes	amp
	pUP-7665	[1]	pYNaf	yes	amp
	pCI-PRE	[2]	pCI-PRE	yes	amp
	pYafB	[1]	pYafB	yes	blast
	pLucf	[3]	pLucf	yes	zeo	replaced by pCLucf

BPV1	pBPVL1-GFP	[4]	phLsf	yes	zeo	Self-packages in TT-BPVL2 stable line. L1-only capsid propagation.
	pBPVL1L2	[4]	pCL?	yes	kan	Self-packages for bulk L1+L2 capsid propagation.
	pADAP-L1	[1]	pCAL	yes	kan
	pZ-L1P	[1]	pZL	yes	amp	BPV1. Use pADAP-L1 instead
	pADAP-L1P	[1]	pAL	yes	amp	BPV1. Use pADAP-L1 instead
	pL1-L2	[1]	pL?Q	yes	kan	BPV1. Use pSheLL instead
	pZ-L2P	[1, 5]	pM?	yes	amp
	pBPV-L2P	[4, 5]	p?P	yes	amp	L2 stable expression plasmid used to make TT-BPVL2 line
	pBPVL2HA	[6]	pM?HA	yes	amp	HA-tagged BPV1 L2
	pSheLL-HA	[6], unpublished	pXL?HA	yes	kan	HA-tagged BPV1 L2 in context of SheLL (L1+L2) expression plasmid

CRPV	pCRPVL1	[7]	p¢Lw	yes	kan
	pCRPVL2	[7]	p¢?	yes	kan

HPV1	pPoLw	unpublished	pPöLw	not yet	kan	HPV1 gives poor L1 yield and HPV1 pseudovirus is poorly infectious.
	poL2	unpublished	pö?	not yet	kan

HPV2	pRaLw	unpublished, EF362755	pRäLw	not yet	kan	HPV2 pseudovirus has a very high particle to infectivity ratio
	paL2	unpublished	pä?	not yet	kan

HPV5	p5L1w	[8] DQ080001	p5L1w	yes	zeo	HPV5 has high particle to infectivity ratio on most cell types
	p5L2w	[9] DQ080001	p5L2w	yes	zeo
	p5L1h	[9]	p5L1h	yes	zeo	slightly better titer yield than p5L1w

HPV6	p6L1	[7]	p6L, p6aL1	yes	kan	Replaced by p6L1B
	p6L1B	[7]	p6LB	yes	blast
	p6L2	[7]	p6?w	yes	kan

HPV16	p16L1-GFP	[10]	phüLsf	Addgene.org	zeo	Self-packages in TT-16L2 stable line. L1-only capsid propagation.
	p16L1h	[11]	püL	yes	amp	Replaced by p16L1-GFP
	p16L2h	[11]	pü?	yes	amp	replaced by p16L2w
	p16L2P	[4]	pü?P	yes	amp	L2 stable expression plasmid used to make TT-16L2 line
	p16L2w	[4]	pü?w	yes	kan
	pXuLL	[12]	pXüL?	yes	zeo	Replaced by p16sheLL
	pOhuL	[13], unpublished	pOhüL	yes	zeo	Minimal SV40 Ori (lacks SV40 promoter activity). Requires Woodworth MTA.
	puL1B	[14]	püL1B, pL1B	yes	blast	Replaced by p16L1-GFP
	puL1fB	[14]	püL1fB	yes	blast	Replaced by p16L1-GFP
	pC175S	[10]	p175ü	yes	zeo	L1 cysteine 175 -> serine. Pseudovirus infectious but incapable of full maturation
	pC428S	[10]	p428ü	yes	zeo	L1 cysteine 428 -> serine. Pseudovirus is extremely fragile and poorly infectious
	p16mL1L2	[10, 15]	pChüL?	yes	zeo	p16L1L2 with L1 C175S mutation
	p16mSheLL	unpublished	pCLLw	yes	amp	p16sheLL with L1 C175S mutation
	p16L2HA	unpublished	pü?HA	yes	kan	HA-tagged HPV16 L2
	p16L1only	Cerqueira et al	p16L1w_revSEAP*	yes	amp	HPV16 L1 expressed from a plasmid that is too be to be packaged. Alternative name “pUL1reverseSEAP”
	pumL1B	Cerqueira et al	pümL1B	yes	blast	HPV16 L1 C428S mutant expression plasmid (puL1B context)
	p16LL2-laugh	pending	p16LL2-laugh	yes	amp	HPV16 L1 co-expression with 5xHA-tagged L2

HPV18	p18L1-GFP	[4]	phëLsf	yes	zeo	Self-packages in TT-18L2 stable line. L1-only capsid propagation.
	p18L1L2	[4]	phëL?	yes	zeo	Self-packages. Bulk L1+L2 capsid propagation
	peL2bhb	[14]	pëL2BHB	yes	kan
	p18L2P	[4]	pë?P	yes	amp	L2 stable expression plasmid used to make TT-18L2 line
	peL1fB	unpublished	pëL1fB	yes	blast	Replaced by p18L1-GFP
	peL1bhb	[14]	peL1bhb	yes	kan	Replaced by p18L1-GFP

HPV31	ptL1w	[7]	ptLw	yes	kan	HPV31 L1 ORF not codon modified. Expression is poor. Replaced by p31sheLL.
	ptL2w	[7]	pt?w	yes	kan	HPV31 L2 ORF not codon modified. Expression is poor. Replaced by p31sheLL

HPV45	p45L1w	[8] DQ080002	p45L1w	yes	zeo
	p45L2w	[8] DQ080002	p45L2w	yes	zeo

DNA replication	pTIH	[1, 16]	pTIH	yes	amp	Stable SV40 T antigen expression construct. Toxic to bacteria – grow at 30ºC or lower
	pdTH	unpublished, [17]	pdTH	not yet	amp	Safer T antigen (p53 and pRB binding sites mutated). Requires Cooper MTA.
	pIND-T	[1]	pDT strategy B	yes	amp
	pRSV-TEX	[16]	pRSV-TEX	Loeken	amp
	pE1	[1]	pE	yes	amp
	pE1-E2	[1]	pEARe	yes	amp
	pIND-E1-E2	[1]	pDEAe	yes	amp
	pIND-E2	[1]	pDAe	yes	amp
	pMEP-E2	Alison McBride	pMEP-E2	yes	amp

Gateway	pDONR-221	Invitrogen	pDONR-222	commercial	kan	Gateway cloning system is useful for manipulation of codon-modified genes.
	pDONR-222	Invitrogen	pDONR-222	commercial	kan	Gateway cloning system is useful for manipulation of codon-modified genes.
	pCDNA-6.2-Dest	Invitrogen	pCDNA-6.2-Dest	commercial	amp or blast	Gateway CMV promoter destination plasmid
	pGwf	[18]	pGwf	yes	zeo	Gateway-adapted destination plasmid using WPRE (Tom Hope)
	phGf	[18]	phGf	yes	zeo	Gateway-adapted destination plasmid with HTLV R-U5 leader
	pFF	[19]	pFF	yes	zeo	Gateway-adapted entry plasmid - cloning site protected by bacterial transcription terminators

Fluorescent L2	puL2f	[9]	pü?f	yes	kan	L2:GFP fusion protein. Resulting fluorescent capsids retain good infectivity
	p16LLfw	unpublished	p16LLfw	yes	amp	L2:GFP fusion protein in context of p16sheLL. Resulting fluorescent capsids cannot transduce the L2:GFP gene.
	pL2-YFP	[4]	pü?Y	yes	kan	L2:yellow fluorescent protein fusion
	pL2-CYFP	[4]	pü?YC	yes	kan	split YFP (bimolecular fluorescence complementation)
	pL2-NYFP	[4]	pü?YN	yes	kan	split YFP (bimolecular fluorescence complementation)
	pCYFP-L2	[4]	pYCü?	yes	kan	split YFP (bimolecular fluorescence complementation)
	pNYFP-L2	[4]	pYNü?	yes	kan	split YFP (bimolecular fluorescence complementation)
	puL2t	unpublished	pü?t	yes	kan	L2 fused to tandem dual tomato. Requires Roger Tsien MTA

RCA cloning	pAsylum	[19]	pAsylum	yes	zeo	Cloning plasmid - MCS protected by bacterial transcription terminators
	pAsylum++	Welch et al.	pAsylum++	yes		pAsylum with improved multiple cloning site

Polyomavirus	pMslc	[20]	pMSLC	AddGene.org	blast	Stable expression of SLC35A1 (CMP-sialic acid transporter)
	pMtB	[20]	pMtB	AddGene.org	blast	MCV small t antigen stable expression
	pMtBS	[20]	pMtBS	AddGene.org	blast	MCV small t antigen with splice donor mutated to avoid unwanted spliced t:blast fusion protein
	pADL*	[20]	pMono-ADL*	AddGene.org	zeo	MCV Large T Antigen stable expression
	pMMt	[20]	pMMt	yes	amp	Bacterial expression of maltose binding protein tagged MCV small t antigen
	pT+Ori	[21]	pMoHf	not yet	amp	MCV autonomous episome plasmid
	pCDNA4C-MCVori	[21]	pCDNA4C-MCVori	not yet	zeo or amp	MCV origin of replication
	pCDNA4C-MCVoriDNI	[21]	pCDNA4C-MCVori	not yet	zeo or amp	MCV origin plus expressed Brd4 fragment
	pMVP2M	unpublished	pMVP2M	yes	amp	Bacterial expression of MBP-MCV VP2 fusion protein
	pHisMVP2	unpublished	pHisMVP2	yes	amp	Bacterial expression of His-tagged MCV VP2 protein
	pC3m	unpublished	pC3m	yes	amp or blast	Mammalian expression of hypothetical MCV VP3 protein
	pC2m	unpublished	pC2m	yes	amp or blast	MCV VP2 expression (isogenic with pC3m)
	pMmw	unpublished	pMmw	yes	amp	Bicistronic MCV VP1-VP2 expression
	pcC18f	unpublished	pcC18f	yes	amp	Constitutively active murine caspase-3 (death gene)
	pcM	unpublished	pcC18f	yes	kan	MCV VP1 under control of CMV promoter, small enough to self-package
	pet2B	unpublished	pe2tB	yes	blast	HPyV7 small T antigen under ferritin promoter. IRES-blasticidin allows stable mammalian expression
	pMe1t	unpublished	pMe1t	yes	amp	Bacterial expression of HPyV6 small t fused to maltose binding protein
	pMe2t	unpublished	pMe2t	yes	amp	Bacterial expression of HPyV7 small t fused to maltose binding protein
	pMBPSV40sT	unpublished	pMBP-SV40sT	not yet	amp	Bacterial expression of SV40 small t fused to maltose binding protein
	pMtw	unpublished	pmtw	yes	zeo	High-yield expression of MCV small t. LT splice donor destroyed.
	pALTOw	Yang et al (submitted)	pALTOw	yes	zeo	MCV ALTO protein expression construct

1. Buck, C.B., et al., Efficient intracellular assembly of papillomaviral vectors.J Virol, 2004. 78(2): p. 751-7.

http://www.ncbi.nlm.nih.gov/pubmed/14694107

2. Buck, C.B., et al., The human immunodeficiency virus type 1 gag gene encodes an internal ribosome entry site.J Virol, 2001. 75(1): p. 181-91.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11119587

3. Gambhira, R., et al., A protective and broadly cross-neutralizing epitope of human papillomavirus L2.J Virol, 2007. 81(24): p. 13927-31.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17928339

4. Buck, C.B., et al., Arrangement of L2 within the papillomavirus capsid.J Virol, 2008. 82(11): p. 5190-7.

5. Zhou, J., et al., Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability.J Virol, 1999. 73(6): p. 4972-82.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10233959

6. Day, P.M., et al., Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression.Proc Natl Acad Sci U S A, 2004. 101(39): p. 14252-7.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15383670

7. Pastrana, D.V., et al., Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.Virology, 2005. 337(2): p. 365-72.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15885736

8. Buck, C.B., et al., Carrageenan is a potent inhibitor of papillomavirus infection.PLoS Pathog, 2006. 2(7): p. e69.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16839203

9. Buck, C.B., et al., Human alpha-defensins block papillomavirus infection.Proc Natl Acad Sci U S A, 2006. 103(5): p. 1516-21.

http://www.ncbi.nlm.nih.gov/pubmed/16432216

10. Buck, C.B., et al., Maturation of papillomavirus capsids.J Virol, 2005. 79(5): p. 2839-46.

http://www.ncbi.nlm.nih.gov/pubmed/15709003

11. Leder, C., et al., Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes.J Virol, 2001. 75(19): p. 9201-9.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11533183

12. Pyeon, D., P.F. Lambert, and P. Ahlquist, Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiation.Proc Natl Acad Sci U S A, 2005. 102(26): p. 9311-6.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15958530

13. Okuley, S., et al., Relationship among location of T-antigen-induced DNA distortion, auxiliary sequences, and DNA replication efficiency.J Virol, 2003. 77(19): p. 10651-7.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12970450

14. Pastrana, D.V., et al., Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.Virology, 2004. 321(2): p. 205-16.

http://www.ncbi.nlm.nih.gov/pubmed/15051381

15. Trus, B.L., et al., Maturation of the human papillomavirus type 16 capsid.manuscript in preparation.

16. Loeken, M., et al., trans-activation of RNA polymerase II and III promoters by SV40 small t antigen.Cell, 1988.55(6): p. 1171-7.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3203384

17. Cooper, M.J., et al., Safety-modified episomal vectors for human gene therapy.Proc Natl Acad Sci U S A, 1997. 94(12): p. 6450-5.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9177238

18. Pastrana, D.V., et al., Quantitation of human seroresponsiveness to Merkel cell polyomavirus.PLoS Pathog, 2009.5(9): p. e1000578.

http://www.ncbi.nlm.nih.gov/pubmed/19750217

19. Schowalter, R.M., et al., Merkel Cell Polyomavirus and Two Previously Unknown Polyomaviruses Are Chronically Shed From Human Skin.Cell Host Microbe, 2010. 7(6): p. 509-15.

http://www.ncbi.nlm.nih.gov/pubmed/20542254

20. Schowalter, R.M., D.V. Pastrana, and C.B. Buck, Glycosaminoglycans and sialylated glycans sequentially facilitate merkel cell polyomavirus infectious entry.PLoS Pathog, 2011. 7(7): p. e1002161.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21829355

21. Wang, X., et al., Bromodomain protein Brd4 plays a key role in Merkel cell polyomavirus DNA replication.PLoS Pathog, 2012. 8(11): p. e1003021.

http://www.ncbi.nlm.nih.gov/pubmed/23144621

Last updated by Buck, Christopher (NIH/NCI) [E] on Jul 03, 2024